DaVita Inc

Denver, CO, United States

DaVita Inc

Denver, CO, United States
SEARCH FILTERS
Time filter
Source Type

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of DaVita Inc. securities (NYSE:DVA) from August 5, 2015 through October 21, 2016, inclusive (the “Class Period”) of the important April 3, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for DaVita investors under the federal securities laws. To join the DaVita class action, go to http://rosenlegal.com/cases-1026.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) DaVita was using American Kidney Fund as a vehicle to facilitate these improper practices; (3) as such, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result, Defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1026.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.


NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of DaVita Inc. securities (NYSE:DVA) from August 5, 2015 through October 21, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for DaVita investors under the federal securities laws. To join the DaVita class action, go to http://rosenlegal.com/cases-1026.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) DaVita was using American Kidney Fund as a vehicle to facilitate these improper practices; (3) as such, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result, Defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1026.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.


News Article | February 15, 2017
Site: www.prweb.com

DaVita Clinical Research (DCR), a specialty contract research organization with services spanning the full spectrum of drug and device development, and Prism Clinical Research, a leader in providing fully integrated clinical research services to pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) has been selected by both companies as an exclusive provider to further prevent duplicate enrollment in clinical trials. Simultaneously enrolling in multiple clinical trials, or duplicate enrollment, has become a serious problem in the clinical research world. A growing number of research volunteers attempt to jump from one study to another without waiting for the appropriate amount of time to lapse. This creates dangerous issues for the drug manufacturer, the research site, the data quality, and, most importantly, the volunteer. “We are pleased to have these two clinical research leaders join our network,” said Dr. Mitchell Efros, CEO of VCT. “Our system will allow both companies to take big steps forward in preventing duplicate enrollment and the risks associated.” VCT maintains a global clinical trial research subject database registry to counter attempts at duplicate enrollment in clinical trial research. The majority of phase I units and an increasingly large number of late phase sites in North America use Verified Clinical Trials, making VCT by far the largest North American clinical research subject database registry in both early and late phase clinical trials. “DCR is passionate about ensuring data quality and research subject safety,” said Amy Young, vice president and general manager of DCR. “Partnering with Prism and using the VCT system is the right thing to do for all our stakeholders.” Experts and leaders in the field of hepato-renal clinical trials, Prism and DCR join a vast network of research sites and pharmaceutical companies in their efforts to prevent duplicate enrollment and other important protocol violations in clinical trials. ”Prism is glad to be participating in this joint effort with our research neighbor, DCR,” said Jeff Cosgrove, president of Prism Research. “We’ve always been proactive in combating dual enrollment, but VCT gives us state-of-the-art technology and processes toward that end.” Located in close proximity to the Minneapolis and St. Paul metropolitan area, Prism and DCR specialize in early phase clinical research in healthy volunteer trials and many patient-based volunteer trials, including those in hepatic and renal insufficiency populations. About Prism Clinical Research Prism Clinical Research is a Twin Cities–based clinical research company committed to the advancement of improved medical knowledge and the community’s health. Since 2005, Prism has provided FDA-approved, investigational pharmaceutical and medical device testing services on behalf of drug and device manufacturers, academic and private physicians, as well as other researchers across Minnesota. About DaVita Clinical Research DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR’s Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, and Real World Healthcare Data are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit http://www.davitaclinicalresearch.com. About Verified Clinical Trials Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials halts duplicate enrollment in clinical trials and defines itself as the world’s leader in the field of database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials, and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value-added services to the clinical research site, CRO, and Pharmaceutical Sponsor that prove invaluable with regards to financial and legal issues and liabilities. Verified Clinical Trials prevents several other key protocol deviations. For more information, RSVP to or visit http://www.verifiedclinicaltrials.com.


News Article | February 15, 2017
Site: www.businesswire.com

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against DaVita Inc. (NYSE: DVA) (“DaVita” or the “Company”) on behalf of purchasers of the Company’s securities between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”). DaVita shareholders who purchased their securities during the Class Period may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class. Shareholders who wish to discuss this action or request additional information about the lawsuit are encouraged to contact Kessler Topaz Meltzer & Check attorneys D. Seamus Kaskela or Adrienne O. Bell at (888) 299-7706 or online at: https://www.ktmc.com/new-cases/davita-inc#join DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end-stage renal disease. At relevant times, DaVita made contributions to the American Kidney Fund (“AKF”), a purported charitable foundation that provides financial assistance toward patients’ health insurance premiums. The shareholder class action complaint alleges that DaVita and certain of its executive officers made a series of materially false and misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects to investors during the Class Period, including the following: (1) that the Company and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) that the Company was using AKF as a vehicle to facilitate these improper practices; (3) that, as a result, DaVita’s revenues and profits were illegally obtained; and (4) that DaVita lacked effective internal controls over financial reporting. The complaint further alleges that, as a result of the foregoing, the defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On August 18, 2016, The Centers for Medicare & Medicaid Services issued a public request for information regarding the alleged steering of Medicare and Medicaid beneficiaries into other plans in order to earn higher reimbursement rates. Following this news, shares of the Company’s stock declined $3.17 per share, or 4.7%, to close on August 19, 2016 at $64.48 per share. Then, on October 23, 2016, the St. Louis Post published an article entitled “DaVita encouraged some low-income patients to enroll in commercial plans” which directly accused DaVita of steering clients to private insurers and utilizing its own money to pay for health insurance premiums through the AKF. Following this news, shares of the Company’s stock declined an additional $2.86 per share, or 4.7%, to close on October 24, 2016 at $58.10 per share. Subsequently, on January 6, 2017, The Wall Street Journal reported that investigators from the U.S. Department of Justice “are probing a controversial arrangement under which kidney-care companies support charitable efforts to help patients pay health-insurance premiums, according to disclosures from major dialysis providers.” Additionally, the article reported that the “Boston U.S. attorney’s office has subpoenaed DaVita Inc. … seeking ‘the production of information related to charitable premium assistance.’” DaVita shareholders may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/davita-inc#join Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.


News Article | February 21, 2017
Site: globenewswire.com

RADNOR, Pa., Feb. 21, 2017 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds DaVita Inc. (NYSE:DVA) (“DaVita” or the “Company”) shareholders that a class action lawsuit has been filed in the United States District Court for the District of Colorado against DaVita on behalf of purchasers of the Company’s securities between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”).  Important Deadline Reminder:  DaVita shareholders who purchased their securities during the Class Period may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class.  For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/davita-inc#join DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end-stage renal disease. At relevant times, DaVita made contributions to the American Kidney Fund (“AKF”), a purported charitable foundation that provides financial assistance toward patients’ health insurance premiums. The shareholder class action complaint alleges that DaVita and certain of its executive officers made a series of materially false and misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects to investors during the Class Period, including the following: (1) that the Company and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) that the Company was using AKF as a vehicle to facilitate these improper practices; (3) that, as a result, DaVita’s revenues and profits were illegally obtained; and (4) that DaVita lacked effective internal controls over financial reporting. The complaint further alleges that, as a result of the foregoing, the defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On August 18, 2016, The Centers for Medicare & Medicaid Services issued a public request for information regarding the alleged steering of Medicare and Medicaid beneficiaries into other plans in order to earn higher reimbursement rates. Following this news, shares of the Company’s stock declined $3.17 per share, or 4.7%, to close on August 19, 2016 at $64.48 per share. Then, on October 23, 2016, the St. Louis Post published an article entitled “DaVita encouraged some low-income patients to enroll in commercial plans” which directly accused DaVita of steering clients to private insurers and utilizing its own money to pay for health insurance premiums through the AKF.  Following this news, shares of the Company’s stock declined an additional $2.86 per share, or 4.7%, to close on October 24, 2016 at $58.10 per share. Subsequently, on January 6, 2017, The Wall Street Journal reported that investigators from the U.S. Department of Justice “are probing a controversial arrangement under which kidney-care companies support charitable efforts to help patients pay health-insurance premiums, according to disclosures from major dialysis providers.” Additionally, the article reported that the “Boston U.S. attorney’s office has subpoenaed DaVita Inc. … seeking ‘the production of information related to charitable premium assistance.’” If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299–7706 or (610) 667–7706, or via e-mail at info@ktmc.com. DaVita shareholders may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member.  A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action.  Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.  For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/davita-inc#join Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.  The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).  The complaint in this action was not filed by Kessler Topaz Meltzer & Check.  For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.


News Article | February 23, 2017
Site: www.prnewswire.com

DENVER, Feb. 23, 2017 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading independent medical group in America and leading provider of kidney care services, has selected Bryan Becker, M.D., MMM, FACP, CPE as chief medical officer of VillageHealth, a subsidiary of DaVita specializing in...


NEW YORK, Feb. 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of DaVita Inc. (“DaVita”) (NYSE:DVA) between August 5, 2015 and October 21, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Colorado. To get more information go to: or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting. On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis. If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.


STEVENSON, Md., Feb. 27, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of DaVita Inc. (NYSE:DVA) (“DaVita” or the “Company”) securities during the period between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in DaVita securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company and senior officers steered patients into unnecessary insurance plans to maximize profits; the Company was using the American Kidney Fund as a vehicle to facilitate the improper practices; and, the Company’s revenues and profits were illegally obtained and it lacked effective internal controls over financial reporting. According to the complaint, following a July 1, 2016 filing of a lawsuit by UnitedHealth against American Renal for fraud, an August 8, 2016 announcement slashing the Company’s operating income guidance, August 18, 2016 news reports regarding requests for information to the Company, and an October 23, 2016 article disclosing that DaVita encouraged low-income patients to enroll in commercial plans, the value of DaVita shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in DaVita securities purchased on or after August 5, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.


STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of DaVita Inc. (NYSE: DVA) (“DaVita” or the “Company”) securities during the period between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in DaVita securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company and senior officers steered patients into unnecessary insurance plans to maximize profits; the Company was using the American Kidney Fund as a vehicle to facilitate the improper practices; and, the Company’s revenues and profits were illegally obtained and it lacked effective internal controls over financial reporting. According to the complaint, following a July 1, 2016 filing of a lawsuit by UnitedHealth against American Renal for fraud, an August 8, 2016 announcement slashing the Company’s operating income guidance, August 18, 2016 news reports regarding requests for information to the Company, and an October 23, 2016 article disclosing that DaVita encouraged low-income patients to enroll in commercial plans, the value of DaVita shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in DaVita securities purchased on or after August 5, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.


News Article | February 16, 2017
Site: www.prnewswire.com

DENVER, Feb. 16, 2017 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced results for the quarter and year ended December 31, 2016. Net income attributable to DaVita Inc. for the quarter and year ended December 31, 2016 was $158 million, or $0.80 per share and $880 million,...

Loading DaVita Inc collaborators
Loading DaVita Inc collaborators